Advanced search
Start date
Betweenand

Investigation of PIMREG interactome in glioblastoma cell lines upon DNA damage caused by temozolomide

Grant number: 22/02295-7
Support Opportunities:Scholarships abroad - Research Internship - Scientific Initiation
Effective date (Start): August 01, 2022
Effective date (End): November 30, 2022
Field of knowledge:Biological Sciences - Genetics - Human and Medical Genetics
Principal Investigator:Leticia Fröhlich Archangelo
Grantee:Maria Vitória de Rizzo Gasparini
Supervisor: Philipp Greif
Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Research place: Ludwig Maximilian University of Munich (LMU Munich), Germany  
Associated to the scholarship:21/06194-8 - Functional analysis of PIMREG deletion in DNA damage repair reporter cells, BP.IC

Abstract

PIMREG, a protein associated with cellular proliferation, is highly expressed in many types of cancer, in particular glioblastoma (GBM). This type of cancer, which affects the central nervous system, is associated with poor prognostic in patients and reoccurs in most cases after surgical resection and chemotherapy, showing resistance, possibly through activation of DNA damage response (DDR). Recent data from our group revealed that genotoxic agents induce PIMREG expression. Moreover, its silencing renders GBM cells sensitive to temozolomide (TMZ) treatment and affects ATR- and ATM-dependent signaling. Thus, PIMREG is involved in DDR and resistance of GBM cells to TMZ. However, where PIMREG might be placed in DNA damage signaling is unknown. Therefore, this study aims to investigate the PIMREG interactome in TMZ-treated GBM cells by mass spectrometry analysis, and identify the DDR regulatory network in which PIMREG participates. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.